Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria

Infection

Volumn 43, Issue 1, 2015, Pages 37-43

  Heizmann, W R ^a   Loschmann P A ^b   Eckmann, C ^c   von Eiff, C ^b   Bodmann, K F ^d   Petrik, C ^b  

^a Orgamed Laborsysteme GmbH   (Germany)

^b PFIZER INC   (United States)

^c Klinikum Peine   (Germany)

^d Klinikum Barnim GmbH   (Germany)

Author keywords

Extended spectrum beta lactamase; Methicillin resistant Staphylococcus aureus; Multiresistant pathogens; Non interventional study; Tigecycline; Vancomycin resistant enterococci

Indexed keywords

CARBAPENEM; CEFEPIME; CEFTAZIDIME; CLINDAMYCIN; GENTAMICIN; METRONIDAZOLE; PIPERACILLIN; SULBACTAM; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; MINOCYCLINE;

ABDOMINAL INFECTION; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CARDIOVASCULAR DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIABETES MELLITUS; DIABETIC FOOT; DISEASE SEVERITY; DRUG EFFICACY; ENTEROCOCCAL INFECTION; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION COMPLICATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; PREVALENCE; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; COMBINATION DRUG THERAPY; DRUG EFFECTS; HOSPITALIZATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMASES; DIABETIC FOOT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MINOCYCLINE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN-RESISTANT ENTEROCOCCI; YOUNG ADULT;

EID: 84925491033     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0691-4     Document Type: Article

References (18)

1. Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother. 2009;10:1213–22.
2. Seifert H, Dowzicky MJ. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline evaluation and surveillance trial (2004–2007). Chemotherapy. 2009;55:241–52.
3. Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, Peters G, Seifert H. German tigecycline evaluation surveillance trial study group. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis. 2009;28:83–90.
4. Kresken M, Leitner E, Seifert H, Peters G, von Eiff C. Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline 1 year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis. 2009;28:1007–11.
5. ®); FDA 2013.
6. ®); EMA 2013.
7. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis. 2005;41(Suppl 5):S354–67.
8. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341–53.
9. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections:a drug use evaluation. BMC Infect Dis. 2010;10:287.
10. Lode HM, Stahlmann R, Kresken M. Multiresistant pathogens––a challenge for clinicians. Zentralbl Chir. 2013;138:549–53.
11. Kujath P, Kujath C. Complicated skin, skin structure and soft tissue infections––are we threatened by multi-resistant pathogens? Eur J Med Res. 2010;15:544–53.
12. Ambrosch A, Haefner S, Jude E, Lobmann R. Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus. Int Wound J. 2011;8:567–77.
13. Meyer E, Schwab F, Gastmeier P. Nosocomial methicillin resistant Staphylococcus aureus pneumonia––epidemiology and trends based on data of a network of 586 German ICUs (2005–2009). Eur J Med Res. 2010;15:514–24.
14. Rubinstein E, Keynan Y. Vancomycin-resistant enterococci. Crit Care Clin. 2013;29:841–52.
15. Bodmann KF, Heizmann WR, von Eiff C, Petrik C, Löschmann PA, Eckmann C. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Chemotherapy. 2012;58:282–94.
16. Ramirez J, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756–62.
17. Heizmann P, Lode H, Heizmann WR. Is monotherapy with beta-lactam antibiotics still up to date? New aspects for treatment of severe infections. Dtsch Med Wochenschr. 2012;137:267–70.
18. Zimmermann JB, Horscht JJ, Weigand MA, Bruckner T, Martin EO, Hoppe-Tichy T, Swoboda S. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline. Int J Antimicrob Agents. 2013;42:436–42.